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Association of a variant in the gene 
encoding for ERV1/ChemR23 with 
reduced inflammation in visceral 
adipose tissue from morbidly obese 
individuals
Cristina López-Vicario1,3, Bibiana Rius1, José Alcaraz-Quiles1, Ana González-Périz1, Ana 
Isabel Martínez-Puchol1, Mireia Casulleras1, Marta Duran-Güell1, Ainitze Ibarzabal2, Ricard 
Corcelles2, Andrés Laguna-Fernández5, Magnus Back5, Esther Titos1,3 & Joan Clària  1,3,4
Obesity comorbidities are closely associated with chronic low-grade adipose tissue inflammation. A 
number of SNPs associated with inflammation has been identified, underscoring the impact of genetic 
determinants on this process. Here, we screened SNPs in genes with pro-inflammatory (IL-1β, IL-6, 
STAT3 and JAK2), anti-inflammatory (IL-10 and SOCS3) and pro-resolving (ERV1/ChemR23) properties 
in 101 obese and 99 non-obese individuals. Among the SNPs analyzed, we identified that individuals 
carrying a C allele in the rs1878022 polymorphism of the ERV1/ChemR23 gene, which encodes for the 
receptor of the pro-resolving mediator RvE1, had increased ERV1/ChemR23 protein expression and 
reduced levels of the inflammatory cytokine IL-6 in adipose tissue. Moreover, patients carrying the 
C allele in homozygosity had lower plasma levels of IL-6, IFN-α2, IL-15, IL-1ra, IL-10, GM-CSF, G-CSF 
and VEGF and enhanced leukocyte responsiveness to RvE1. C-carriers also exhibited decreased TAG 
to HDL ratio, a surrogate marker of insulin resistance and a predictor of incident fatty liver. Finally, we 
confirmed in vivo that the ERV1/ChemR23 receptor regulates systemic and tissue inflammation since 
mice lacking ERV1/ChemR23 expression showed increased IL-6 levels in adipose tissue and peritoneal 
macrophages. Together, our study identified an ERV1/ChemR23 variant that protects patients with 
obesity from excessive inflammatory burden.
Obesity is defined as increased adipose tissue mass and is the net result of an imbalance between energy intake 
and energy expenditure. Obesity is a highly prevalent and rapidly evolving health concern, and in recent years, 
has acquired the characteristics of a global pandemic disease1. The health impact of this pandemic is not only 
the burden of excessive weight but also the predisposition to frequently present comorbidities such as insulin 
resistance and type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, hypertension and cardiovascular 
disease2.
Recent studies have confirmed the positive association between comorbidities and inflammation in obesity. 
In this regard, insulin resistance and non-alcoholic fatty liver disease in obese individuals have been linked to 
a chronic state of low-grade inflammation in adipose tissue3,4. Recent evidence indicates that this persistent 
inflammation in obese adipose tissue is characterized by an unbalanced production of pro-inflammatory versus 
anti-inflammatory and pro-resolving mediators5–7. Among the latter, resolvins are the most widely known spe-
cialized pro-resolving mediators (SPMs) and they play a prominent role in inflammation because of their ability 
to expedite resolution with minimal damage to the surrounding tissue (reviewed in 8). Indeed, a deficit in SPM 
1Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain. 2Department of 
Gastrointestinal Surgery, Hospital Clínic, IDIBAPS, Barcelona, Spain. 3CIBERehd, University of Barcelona, Barcelona, 
Spain. 4Department of Biomedical Sciences, University of Barcelona, Barcelona, Spain. 5Centre for Molecular 
Medicine, Department of Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University 
Hospital, Stockholm, Sweden. Correspondence and requests for materials should be addressed to C.L.-V. (email: 
clopezv@clinic.ub.es) or J.C. (email: jclaria@clinic.cat)
Received: 28 July 2017
Accepted: 3 November 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIEntIfIC RepoRTs | 7: 15724  | DOI:10.1038/s41598-017-15951-z
levels interferes with the timely resolution of inflammation as recently demonstrated in patients with chronic 
metabolic diseases and experimental models of obesity7,9–12. Although the biological actions of SPMs have been 
a subject of ample research, whether these lipid mediators and their role in the resolution process are influenced 
by genetic factors is currently unknown.
In the current study, we identified a functional SNP in the gene encoding for ERV1/ChemR23, the recep-
tor that recognizes the anti-inflammatory and pro-resolving mediator resolvin E1 (RvE1), a SPM endogenously 
derived from the long-chain highly-unsaturated fatty acid, eicosapentaenoic acid (EPA)13,14. In particular, in this 
study we provide evidence that in comparison to obese individuals carrying the ancestral allele T, those individ-
uals carrying the C variant in the ERV1/ChemR23 rs1878022 SNP exhibit a higher expression of this receptor 
in visceral adipose tissue, a reduced degree of adipose tissue inflammation and hepatic insulin resistance and 
significantly lower levels of circulating inflammatory cytokines and chemokines. In addition, LPS-stimulated 
leukocytes from obese individuals carrying the C variant were more responsive to RvE1, suggesting that this var-
iant enhances RvE1-induced anti-inflammatory responses. The role of ERV1/ChemR23 in the regulation of the 
inflammatory tone was confirmed in mice lacking this receptor (ChemR23−/−), which, as compared to wild-type 
(WT) mice, displayed a greater degree of inflammation in visceral adipose tissue, liver tissue and peritoneal mac-
rophages. Altogether, our data provide evidence of the influence of genetic factors on SPM actions and resolution 
of inflammation in patients with obesity.
Results
The demographic and clinical characteristics of the patient cohorts are shown in Table 1. One hundred one out 
of 200 participants were morbidly obese and 68% were women. The obese cohort was significantly younger than 
the non-obese group (63 ± 3 vs. 45 ± 1 years, P < 0.001). Non-obese patients had a body mass index (BMI) of 
26.4 ± 0.9 kg/m2 whereas patients from the obese cohort had a significantly increased BMI (45.3 ± 0.7 kg/m2). 
There were no statistically significant differences in serum glucose, triglycerides (TG), total cholesterol, 
gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) lev-
els between the two study cohorts (Table 1). No statistical significant differences were observed in blood leuko-
cyte, monocyte and platelet counts (Table 1).
Using TaqMan® allelic discrimination we first analyzed seven SNPs in genes involved in the regulation of 
the inflammatory response: interleukin (IL)-1β (rs1143634), IL-6 (rs1800795), signal transducer and activator 
of transcription 3 (STAT3, rs8069645), Janus kinase 2 (JAK2) (rs7849191), IL-10 (rs1800871), suppressor of 
cytokine signaling 3 (SOCS3, rs8064821) and ERV1/ChemR23 (rs1878022). These SNPs have previously been 
associated with inflammation or insulin resistance in the setting of metabolic, hepatic or proliferative disorders 
(Supplementary Table 1). All the selected candidate gene variants had minor allele frequencies (MAF) consistent 
with those reported in the HapMap project CEPH-CEU (Utah Residents with Northern and Western European 
Ancestry) (Table 2). The distribution of genotypes for all the SNPs was consistent with Hardy-Weinberg equi-
librium (Table 2). Single locus analysis under the dominant inheritance model in the whole group of patients of 
the study identified a minor allele variant (C) in the ERV1/ChemR23 DNA gene sequence in association with the 
cohort of obese individuals (Table 3). This SNP (rs1878022) is an intronic variant located within ERV1/ChemR23 
on human chromosome 12 (Supplementary Fig. 1). This gene encodes for a seven transmembrane G-protein 
receptor that binds the specialized pro-resolving lipid mediator RvE114 as well as chemerin, a protein that partic-
ipates in numerous cellular processes such as adipogenesis15. No other SNP studied was detected in association 
with the obese cohort (Table 3). TaqMan®SNP genotyping results of the ERV1/ChemR23 rs1878022 SNP were 
confirmed by Sanger DNA sequencing (Supplementary Fig. 2A). The genotype analysis revealed that the CC and 
Non-obese Obese
n = 99 n = 101
♂/♀ (%) 42/58 32/68
Age (years) 63 ± 3 45 ± 1*
BMI (kg/m2) 26.4 ± 0.9 45.3 ± 0.7*
Glucose (mg/dL) 112.6 ± 13.0 119.4 ± 5.6
Triglycerides (mg/dL) 119.8 ± 28.1 133.7 ± 5.2
Cholesterol (mg/dL) 168.7 ± 21.4 189.9 ± 3.7
GGT (IU/L) 36.0 ± 9.0 39.2 ± 5.7
ALT (IU/L) 22.7 ± 7.4 29.8 ± 2.3
AST (IU/L) 20.3 ± 4.5 23.4 ± 1.4
Leukocytes (109/L) 7.9 ± 0.6 8.4 ± 0.2
Monocytes (109/L) 0.4 ± 0.1 0.5 ± 0.1
Platelets (109/L) 273.9 ± 19.2 306.6 ± 8.1
Table 1. Clinical characteristics and anthropometric measurements of the study participants. BMI: body mass 
index; ALT: alanine aminotransferase; AST: aspartate aminotransferase. Non-obese individuals (BMI < 29.9), 
Obese subjects (BMI > 29.9). Normal reference values: glucose 65–110 mg/dL, triglycerides 50–150 mg/dL, 
cholesterol 148–247 mg/dL, GGT, ALT and AST 5–40 IU/L, leukocytes 4.5–10.5 × 109/L, monocytes 0.14–
0.72 × 109/L and platelets 150–400 × 109/L. Results are expressed as mean ± SEM. *P < 0.001 versus Non-obese.
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TC genotypes were more frequent in obese individuals whereas the TT genotype was more frequent in non-obese 
individuals (Supplementary Fig. 2B).
We next determined whether the ERV1/ChemR23 variant had a functional role in omental adipose tissue 
from obese individuals. The morphometric assessment of ERV1/ChemR23 protein levels as detected by immu-
nohistochemistry revealed increased positive staining for this receptor in adipose tissue from obese patients 
carrying the C allele, reaching statistical significance in individuals that were homozygous (CC) (Fig. 1A). The 
adipose tissue expression of ERV1/ChemR23 at the mRNA level was significantly higher in heterozygotes of 
obese patients carrying the C allele (Fig. 1B). Notably, IL-6, a marker of inflammation, was significantly reduced 
in omental adipose tissue from obese individuals carrying the C allele (Fig. 1C). We were able to confirm the 
inverse relationship between the expression of ERV1/ChemR23 and IL-6 in 3T3-L1 adipocytes, which levels of 
ERV1/ChemR23 expression increase during the process of differentiation (Supplementary Fig. 3). Of interest, no 
differences in CD68, a macrophage surface marker, were observed in omental adipose tissue from obese individ-
uals carrying the C allele (Fig. 1D), suggesting that variations in the degree of inflammation associated with the 
ERV1/ChemR23 variant were probably related to changes in the expression of inflammatory genes rather than to 
the number of infiltrated macrophages.
We next explored whether changes in the degree of adipose tissue inflammation in obese patients carrying the 
different ERV1/ChemR23 rs1878022 genotypes were mirrored by differential circulating levels of cytokines. As 
shown in Fig. 2A, obese patients carrying the minor C allele had lower plasma IL-6 levels than those carrying the 
TT genotype, reaching statistical significance in homozygous CC individuals. Other inflammatory and immuno-
modulatory cytokines such as interferon alpha-2 (IFN-α2) and IL-15 were also significantly reduced in plasma 
from CC individuals (Fig. 2B). Of interest, decreased levels of anti-inflammatory (interleukin-1 receptor antago-






IL-1β (rs1143634) G (0.81) A (0.19) A (0.13) 0.975
IL-6 (rs1800795) G (0.81) C (0.19) C (0.14) 0.072
STAT3 (rs8069645) A (0.69) G (0.31) G (0.33) 0.547
JAK2 (rs7849191) T (0.57) C (0.43) C (0.49) 0.113
IL-10 (rs1800871) G (0.59) A (0.41) A (0.43) 1.309
SOCS3 (rs8064821) C (0.81) A (0.19) A (0.20) 2.623
ERV1/ChemR23 (rs1878022) T (0.69) C (0.31) C (0.32) 3.397
Table 2. Common allele frequency, minor allele frequency (MAF), reported MAF and Hardy-Weinberg 
equilibrium for the SNPs genotyped in the study. *Data from the HapMap project CEPH-CEU (Utah Residents 
with Northern and Western European Ancestry). χ2 value = 3.841 (1 degree of freedom, p value < 0.05).
Gene and SNP Inheritance Model Odds ratio CI 95% P value
IL-10 (rs1800871)
Dominant GG/GA+AA 1.384 (0.793–2.481) n.s.
Recessive AA/GG+GA 1.894 (0.672–5.339) n.s.
Overdominant GA/GG+AA 1.148 (0.648–2.032) n.s.
IL-6 (rs1800795)
Dominant GG/GC+CC 1.080 (0.618–1.886) n.s.
Recessive CC/GG+GC 0.495 (0.216–1.133) n.s.
Overdominant GC/GG+CC 1.523 (0.865–2.683) n.s.
STAT3 (rs8069645)
Dominant AA/AG+GG 1.236 (0.704–2.170) n.s.
Recessive GG/AA+AG 0.886 (0.371–2.114) n.s.
Overdominant AG/AA+GG 1.353 (0.739–2.478) n.s.
SOCS3 (rs8064821)
Dominant CC/CA+AA 0.579 (0.298–1.125) n.s.
Recessive AA/CC+C 0.310 (0.061–1.574) n.s.
Overdominant ACA/CC+AA 0.699 (0.345–1.415) n.s.
ERV1/ChemR23 (rs1878022)
Dominant TT/TC+CC 1.704 (0.965–3.010) <0.05
Recessive CC/TT+TC 1.355 (0.705–2.604) n.s.
Overdominant TC/TT+CC 1.380 (0.770–2.474) n.s.
JAK2 (rs7849191)
Dominant TT/TC+CC 0.875 (0.402–1.904) n.s.
Recessive CC/TT+TC 0.816 (0.459–1.450) n.s.
Overdominant TC/TT+CC 1.130 (0.648–1.968) n.s.
IL-1β (rs1143634)
Dominant GG/GA+AA 0.749 (0.421–1.331) n.s.
Recessive AA/GG+GA 0.978 (0.352–2.718) n.s.
Overdominant GA/GG+AA 0.726 (0.393–1.340) n.s.
Table 3. Analysis of association for each SNP with the cohort of obese individuals according to dominant, 
recessive and overdominant inheritance models.
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and granulocyte colony stimulating factor (G-CSF)) (Fig. 2D) and pro-angiogenic (vascular endothelial growth 
factor (VEGF)) (Fig. 2E) cytokines were also seen in obese patients carrying the C allele. No differences were 
found in IL-8 and monocyte chemoattractant protein-1 (MCP-1) (Supplementary Fig. 4). In view of these find-
ings, we hypothesized that circulating leukocytes from individuals carrying the C variant in the ERV1/ChemR23 
receptor, which recognizes the pro-resolving mediator RvE1, would exhibit a more favorable anti-inflammatory 
environment than leukocytes from non-C carriers. To address this, we triggered LPS-induced inflammation in 
leukocytes from C-carrier and non-C carrier individuals in the presence or absence of RvE1 and quantified the 
inflammatory response by means of IL-6 expression. As shown in Fig. 2F, leukocytes from C-carrier patients were 
more sensitive to RvE1 and showed a higher capacity to attenuate the LPS induction of IL-6 than those isolated 
from non-C carriers (∼34% vs 15% reduction).
Obesity-induced inflammation is a well-established risk factor for metabolic comorbidities, such as insulin 
resistance and non-alcoholic fatty liver disease. As shown in Fig. 3A, obese patients carrying the minor C allele 
in homozygosity exhibited a significantly reduced TG to the high-density lipoprotein cholesterol (HDL-c) ratio, 
a surrogate marker of insulin resistance and a predictor of incident fatty liver and increased risk for cardiovas-
cular disease in human subjects independently of obesity16–19. Plasma insulin and GGT showed a trend towards 
reduced levels in patients carrying the minor C allele (Fig. 3B and C). Together, these findings identify obese 
patients carrying the minor C allele as a subset of subjects with a lower-risk of metabolic syndrome.
To confirm that changes in the expression of ERV1/ChemR23 are linked to variations in the degree of sys-
temic and tissue inflammation we next explored the inflammatory phenotype of mice lacking ERV1/ChemR23 
(ERV1/ChemR23−/− mice). As compared to WT mice, no differences were observed in ERV1/ChemR23−/− mice 
with respect to body weight and white adipose tissue and liver to body weight ratios (Supplementary Table 2). 
No changes were seen in total serum cholesterol, HDL-c, low-density lipoprotein cholesterol (LDL-c) and TGs 
(Supplementary Table 2). As expected, mice lacking ERV1/ChemR23 showed decreased expression of this recep-
tor in peritoneal macrophages, visceral adipose tissue and liver (Fig. 4A). Compared to their WT controls and 
consistent with the view that ERV1/ChemR23 is a key regulator of inflammation, ChemR23−/− mice had sig-
nificantly increased expression of the pro-inflammatory cytokine IL-6 in peritoneal macrophages and adipose 
tissue (Fig. 4B). MCP-1 was also up-regulated in adipose tissue of ERV1/ChemR23−/− mice (Supplementary 
Fig. 5). Expression of IL-6 were slightly higher in livers from ERV1/ChemR23−/− mice, although differences 
did not reach statistical significance (Fig. 4B). The absence of changes in hepatic IL-6 in ChemR23−/− mice were 
confirmed at the protein level (Supplementary Fig. 6). ERV1/ChemR23−/− mice had increased levels of ALT, a 
surrogate serum marker of liver injury, and showed an increasing trend in insulin resistance and serum glucose 
levels (Fig. 5A and B). However, no evidence of steatosis was observed in these mice, since the hepatic expression 
of CD36 and SREBP-1c, two genes invariably up-regulated during the steatotic process, remained unchanged 
(Fig. 5C).
Figure 1. Overexpression of ERV1/ChemR23 in omental adipose tissue from obese individuals carrying the 
C allele. (A) Immunohistochemical staining of ERV1/ChemR23 protein in omental adipose tissue of obese 
patients carrying the TT (n = 16), TC (n = 16) and CC (n = 17) genotypes. Representative images with a 200X 
magnification are shown (left). Quantification of the percentage of the positive staining area is shown on the 
right. (B) Real-time PCR analysis of ERV1/ChemR23 mRNA expression. (C) IL-6 mRNA expression (D) CD68 
mRNA expression. The data represent the mean ± SEM.
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Discussion
Inflammation plays a critical role in host defense against invasive pathogens and tissue and wound repair. 
Inflammation not only occurs in response to pathogens but can also be induced without active infection (sterile 
inflammation). This is the case of obesity, a condition in which the immune system is engaged in low-grade 
inflammatory response in several insulin-sensitive tissues, especially adipose tissue20. The stressors of this inflam-
matory response are diverse including over-nutrition, high-levels of lipids, free fatty acids and glucose, oxidative 
stress and hypoxia secondary to the expansion of adipose tissue volume21. A particular feature of obesity-induced 
inflammation is that it is chronic and of low intensity20. Importantly, this state of chronic low-grade inflamma-
tion is central in the pathogenesis of obesity-associated comorbidities such as insulin resistance3,4. For example, 
insulin resistance closely correlates with visceral obesity, ectopic fat deposition in muscle and liver, hypertension, 
dyslipidemia, endothelial dysfunction and elevated levels of adipokines such as TNFα, IL-6 and leptin22,23. This 
Figure 2. Circulating levels of cytokines in obese individuals carrying the different ERV1/ChemR23 genotypes. 
Plasma levels of IL-6 (A), IFN-α2, IL-15 (B), IL-1ra, IL-10 (C), GM-CSF and G-CSF (D), and VEGF (E) 
determined by the Luminex assay according to the ERV1/ChemR23 SNP genotype. (F) IL-6 expression in 
polymorphonuclear leukocytes isolated from non-C carrier and C-carrier individuals incubated with LPS 
(100 ng/ml) in the absence or presence of RvE1 (10 nM) for 2 h. The data represent the mean ± SEM of the 
individuals with TT (n = 16), TC (n = 16) and CC (n = 17) genotypes. *p < 0.05 and **p < 0.001 versus TT.
Figure 3. Individuals with the homozygous C variant in the ERV1/ChemR23 SNP show reduced insulin 
resistance. (A) TG to the high-density lipoprotein cholesterol (HDL-c) ratio. (B) Serum insulin. (C) Serum 
GGT levels. The data represent the mean ± SEM of the individuals with TT (n = 16), TC (n = 16) and CC 
(n = 17) genotypes. *p < 0.01 versus TC and a, p < 0.05 versus TT.
www.nature.com/scientificreports/
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inflammatory environment progresses to an overproduction of reactive oxygen species and adipokines, which 
chronify the inflammatory response ultimately leading to obesity-related complications3,4.
Given that persistent unresolved inflammation is detrimental to the host, higher organisms have evolved 
protective mechanisms to ensure resolution of the inflammatory response in a specific time-limited manner24. 
Among the mechanisms that facilitate resolution, the biosynthesis of SPMs, a class of endogenous lipid mediators 
which includes, among others, resolvins, protectins and maresins generated from the omega-3 fatty acids EPA 
and docosahexaenoic acid (DHA), has been described to efficiently resolve inflammation with minimal damage 
to the surrounding tissue8,25. In particular, RvE1 is formed from EPA during the resolution phase of acute inflam-
mation via cell-cell interactions such as endothelial cell-leukocyte interactions13,14. RvE1 biosynthesis involves 
cells bearing acetylated cyclooxygenase (COX)-2 and cells that possess 5-lipoxygenase (5-LOX), although it can 
also be generated by cytochrome P450 processing of EPA26. RvE1 blocks and counterregulates the production 
of inflammatory mediators, inhibits polymorphonuclear leukocytes transendothelial migration and stimulates 
macrophages to enhance phagocytosis and clearance of apoptotic leukocytes27,28. RvE1 actions are mediated by 
its binding to ERV1/ChemR23, a G-protein coupled receptor expressed in monocytes/macrophages, immature 
dendritic cells, and adipocytes14,28. Therefore, our observation that cells and tissues from patients carrying the C 
variant in the rs1878022 polymorphism of the ERV1/ChemR23 gene exhibit a more favorable anti-inflammatory 
environment in the context of higher expression of this receptor can be explained by the fact that these individu-
als are more responsive to the anti-inflammatory actions of RvE1. Indeed, our data demonstrate that leukocytes 
from C carriers show enhanced responsiveness to RvE1 in blocking LPS-induced inflammation than those from 
non-C carriers. Similar results were obtained in differentiating adipocytes in which higher expression of the RvE1 
receptor ERV1/ChemR23 inversely correlated with lower expression of the inflammatory cytokine IL-6. However, 
it must be considered that ERV1/ChemR23 has other ligands, such as the peptide chemerin, which possesses 
antimicrobial and immunomodulatory properties29,30. Consequently, we cannot exclude mechanism other that 
RvE1 such as that described by Luangsay et al.31, who described that the ERV1/ChemR23 receptor mediates 
anti-inflammatory actions of chemerin in a lung disease model.
Several SNPs located within the ERV1/ChemR23 DNA sequence have been identified by genome-wide asso-
ciation studies demonstrating the impact of these variants on the natural course of multifactorial diseases. For 
example, rs17040430 has been associated with mental disorders in a cohort of 4436 patients with schizophrenia 
and/or bipolar disorder32. Another ERV1/ChemR23 SNP, rs107291463, has been strongly associated with the 
development of erectile dysfunction after radiotherapy33. Finally, the SNP rs1878022, identified in the current 
Figure 4. Mice lacking ERV1/ChemR23 display increased IL-6 expression. (A) ERV1/ChemR23 mRNA 
expression in visceral adipose tissue, peritoneal macrophages and liver from wild-type (WT) and KO mice. 
(B) IL-6 mRNA expression in these tissues from WT and KO mice. The data represent the mean ± SEM of WT 
(n = 12) and KO (n = 12) mice. *p < 0.05 and **p < 0.01 versus WT.
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study as a protective variant against obesity-induced inflammation, has previously been demonstrated to be asso-
ciated with poor overall survival in non‐small cell lung cancer patients34. As far as we know, our study is the first 
investigation in which a genetic variant of ERV1/ChemR23 has been associated with a higher degree of inflam-
mation in both visceral adipose tissue and systemic circulation. Indeed, our observation reinforces the idea that 
resolution of inflammation, as well as many other biological processes, is influenced by our genetic background. 
In a previous report, Simiele and collaborators reported the presence of a SNP variant in the promoter of the gene 
coding for formyl peptide receptor 2 (FPR2)/ALX, a G-protein-coupled receptor that binds the pro-resolving 
mediators lipoxin A4 and RvD135. These investigators reported that individuals carrying this SNP had a reduced 
expression of the pro-resolving FPR2/ALX receptor and were more vulnerable to developing cardiovascular 
disease35. On the other hand, Kim and collaborators have recently reported a gene variant in FPR2/ALX that 
conferred significant protection to asthma patients against the development of aspirin exacerbated respiratory 
diseases, which in this case was associated with an increased protein expression of this pro-resolving receptor36. 
Finally, a previously unappreciated pattern of methylation that makes FPR2/ALX transcriptionally inaccessible, 
leading to a low expression of this pro-resolving receptor at both mRNA and protein level has recently been 
uncovered37. This latter finding suggests that the expression of pro-resolving receptors is not only dependent on 
genetic variants but is also regulated by epigenetic factors.
An interesting aspect of our study was that we were able to confirm our findings in obese individuals at exper-
imental level describing a close relationship between ERV1/ChemR23 expression and the degree of inflammation 
Figure 5. Mice lacking ERV1/ChemR2 (KO) show increased liver injury. (A) Serum levels of AST and ALT in 
wild-type (WT, n = 12) and KO (n = 12) mice. (B) Serum TG to the high-density lipoprotein cholesterol (HDL-
c) ratio in these mice. (C) Hepatic expression of CD36 and SREBP-1c in WT and KO mice. The data represent 
the mean ± SEM. *p < 0.01 versus WT.
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in mice lacking the ERV1/ChemR23 receptor. In these mice, we confirmed that the expression of this receptor 
inversely correlates with the levels of inflammatory markers in visceral adipose tissue. Our findings are consistent 
with those by Demoor et al.38, who reported that mice lacking ERV1/ChemR23 exhibit an impaired resolution 
of cigarette smoke-induced inflammation. Moreover, our data point to the presence of insulin resistance in these 
mice, results which are consistent with those previously reported by Ernst et al.39 showing that ERV1/ChemR23 
knockout mice are glucose intolerant. However, these findings do not agree with those from Rouger et al.40, who 
reported unaltered glucose tolerance in these mice.
In summary, the results of the present study provide evidence that a SNP variant in the ERV1/ChemR23 gene 
is associated with increased expression of this receptor and with a lower degree of tissue inflammation and cir-
culating levels of cytokines and chemokines in a population of morbidly obese individuals. Importantly, patients 
carrying this SNP variant exhibit a lower risk of obesity-associated comorbidities such as insulin resistance. 
The inverse relationship between ERV1/ChemR23 expression and the degree of inflammation was confirmed 
in ERV1/ChemR23 knockout mice, which displayed a greater degree of inflammation in both visceral adipose 
tissue, liver and peritoneal macrophages. Collectively, our data indicate that the ERV1/ChemR23-RvE1 axis is 
susceptible to modulation by genetic changes, corroborating that the resolution of inflammation is also regulated 
at the DNA level.
Material and Methods
Study participants. One hundred one patients with morbid obesity (BMI > 30 kg/m2) undergoing laparo-
scopic bariatric surgery and 99 non-obese patients (BMI < 30 kg/m2) undergoing elective gastric surgery were 
included in the study. The BMI was calculated as mass/(height)2. Individuals with inflammatory bowel disease or 
cancer and obese patients with previous bariatric surgery were excluded from the study. Demographic, clinical 
data and drug use were collected from the electronic medical records of the patients. Venous blood samples (5 ml) 
were collected in EDTA-tubes and visceral (omental) adipose tissue samples were intra-operatively harvested 
with sharp dissection for genotyping and gene expression analysis, respectively. Harvested adipose tissue samples 
were weighed on a precision balance, washed twice with DPBS, cut into 100 mg pieces, placed in either 10% for-
malin or snap-frozen in liquid nitrogen and stored in Nunc® CryoTubes at −80 °C for further analysis. The study 
protocol (protocol #2012-7239) was approved by the Investigation and Ethics Committee of the Hospital Clínic 
and all methods were carried out in accordance with the guidelines and regulations dictated by this Committee. 
Written informed consent was obtained from all participants.
Biochemical analyses and cell count. Serum concentrations of glucose, total cholesterol, HDL-c, TG, 
ALT, AST and GGT and blood leukocyte, monocyte and platelet counts were determined by standard laboratory 
procedures. LDL-c was calculated as (total cholesterol – HDL-c) – (TG/5).
Assessment of insulin resistance. Insulin resistance was assessed by calculating the ratio between serum 
TG and HDL-c levels, as a surrogate marker of insulin resistance and a predictor of incident fatty liver and 
increased risk for cardiovascular disease in human subjects independently of obesity16–19.
DNA extraction. Blood samples were centrifuged at 800 g for 15 min and genomic DNA was isolated from 
the buffycoat containing the nucleated cells using the Qiasymphony MIDI Kit in a Qiasymphony SP instru-
ment (Qiagen, Hilden, Germany). In some patients, DNA was extracted from visceral adipose tissue using the 
Qiasymphony MINI Kit (Qiagen) for tissue samples.
Allelic Discrimination. Seven SNPs from seven candidate genes involved in the inflammatory response 
were screened. SNP selection was based on the inclusion of genes related to the inflammatory process. Among 
these, the screening included SNPs in genes coding for pro-inflammatory (IL-1β, IL-6, STAT3 and JAK2), 
anti-inflammatory (IL-10 and SOCS3) and pro-resolving (ERV1/ChemR23) factors and signaling pathways. 
The selection was based on previously published results showing allelic associations between these polymor-
phisms and human diseases (Supplementary Table 1). SNPs were genotyped using TaqMan®SNP Genotyping 
assays in an ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). The TaqMan®SNP 
Genotyping assay was based on an oligonucleotide (probe) labeled with a reporter fluorescent dye (FAMTM or 
VICTM) and a quencher dye (TAMRATM), linked covalently to the 5′ and 3′ end, respectively. The TaqMan probes 
used for genotyping were: IL-10 rs1800871 (C_1747362_10), IL-6 rs1800795 (custom assay), STAT3 rs8069645 
(C_30301828_10), SOCS3 rs8064821 (C_43672951_10), ERV1/ChemR23 rs1878022 (C_11698200_10), JAK-2 
rs7849191 (C_2008287_10) and IL-1β rs1143634 (C_9546517_10). Reactions took place in 96-well plates in 25 µl 
of total volume containing 11.25 µl of genomic DNA (1.77 ng/µl), 12.5 µl of Master Mix and 1.25 µl of a mix of 
probes and primers. During PCR amplification, the probe specifically anneals between the forward and reverse 
primer sites, and the nuclease activity of Taq DNA polymerase cleaves the probe and frees the fluorescent dye 
allowing allele identification. Data were analyzed by Sequence Detector Software (SDS) version 2.1 (Applied 
Biosystems).
DNA Sequencing. The TaqMan®SNP Genotyping results were confirmed by Sanger DNA sequencing. PCR 
products were purified using the ExcelaPure™ 96-Well ultrafiltration-based system (EdgeBio, Gaithesburg, MD) 
and sequencing reactions were performed with the BigDye Terminator v.3.1 (Applied Biosystems). Sequencing 
reactions were cleaned-up by removal of unincorporated dyes with the Performa® DTR system (EdgeBio) before 
electrophoresis analysis in an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems).
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Immunohistochemistry analysis. Adipose tissue samples were routinely fixed in 10% buffered forma-
lin, embedded in paraffin and sectioned into 2-mm-thick sections for immunohistochemistry of primary rabbit 
anti-human ERV1/ChemR23 antibody (dilution 1:100; LifeSpan Biosciences, Seattle, WA) and H&E counter-
staining at the Pathology Department of the Hospital Clínic. Sections were visualized at x200 magnification in a 
Nikon Eclipse E600 microscope (Tokyo, Japan).
RNA extraction, reverse transcription and real-time PCR analysis. Isolation of total RNA was per-
formed from 70 mg (human) and 40 mg (mouse) of adipose tissue by phenol-chloroform extraction using the 
TRIzol reagent. Dry RNA pellets were resuspended into 20 μl of DEPC water and RNA concentrations were 
assessed in a NanoDrop-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Five-hundred ng 
of total RNA were taken for cDNA synthesis using the High-Capacity cDNA Archive Kit (Applied Biosystems). 
Validated and pre-designed TaqMan® Gene Expression Assays were used to quantify IL-6 (ID: Hs00985639_m1; 
Mm00446190_m1), ERV1/ChemR23 (ID: Hs01386064_m1; Mm02619757_s1), MCP-1 (ID: Mm00441242_m1) 
and CD68 (ID: Hs00154355_m1; Mm03047343_m1) using β-actin (ID: Hs99999903_m1; Mm02619580_g1) as 
endogenous control. Real-time PCR amplifications were carried out in an Applied Biosystems 7900HT Fast Real 
Time PCR System. The amount of target gene, normalized to β-actin and relative to a calibrator, was determined 
by the arithmetic formula 2−ΔΔCt described in the Comparative Ct Method (http://docs.appliedbiosystems.com/
pebiodocs/04303859.pdf). Data analysis was performed using RQ Manager 1.2 (Applied Biosystems).
Assessment of cytokines and chemokines by Luminex xMAP technology. Levels of cytokines 
including IL-6, IL-8, IL-15, MCP-1, TNF-α, G-CSF, GM-CSF, IL-10, IL-1ra, VEGF and IFN-α2 were determined 
in 25 μl of plasma using a custom-made multiplexed bead-based immunoassay (Milliplex MAP Human Cytokine/
Chemokine Magnetic Bead Panel; Merck Millipore, Billerica, MA) in a Luminex 100 Bioanalyzer (Luminex Corp., 
Austin, TX). Briefly, 25 μL of plasma were added to each well before the addition of 25 μL of premixed microbe-
ads. The plate was incubated overnight at 4 °C with shaking, then washed and reincubated with 25 μL of detection 
antibody for 1 hour. The plate was washed again and incubated with 25 μL of streptavidin-phycoerythrin for 
30 minutes. Finally, after 2 washes the beads were resuspended with 100 μL of sheath fluid and analyzed in the 
Luminex 100 system. The readouts were analyzed with the standard version of Milliplex Analyst software (Merck 
Millipore). A five-parameter logistic regression model was used to create standards curves (pg/ml) and to calcu-
late the concentration of each sample.
Measurement of IL-6 levels. Levels of IL-6 in homogenates from liver tissue were determined by a specific 
enzyme-linked immunoassay (Mouse IL-6 ELISA Kit; Abcam, ab46100).
Isolation of human peripheral blood leukocytes. Human peripheral blood leukocytes were isolated 
from C carrier and non-C carrier individuals. Briefly, blood samples collected with EDTA were centrifuged at 
200 g for 10 min, and sedimented cells were incubated with pre-warmed ammonium-chloride-potassium lysis 
buffer for 5 min at room temperature to remove red blood cells. Samples were then centrifuged at 400 g for 
10 min and the supernatants decanted. The red blood cell lysis procedure was repeated twice for 10 min each, 
and the resultant pellet was finally washed with DPBS without calcium and magnesium. The isolated leukocytes 
were resuspended in RPMI 1640 medium containing penicillin (100 U/mL) and streptomycin (100 U/mL) and 
L-glutamine (4 mM) with 0.5% FBS. Leukocytes at a density of 3 × 106 cells/mL were stimulated with LPS (100 
ng/ml) for 2 hours at 37 °C (5% CO2) in the absence or presence of RvE1 (10 nM). At the end of the incubations, 
cells were centrifuged at 400 g for 10 minutes at 4 °C and pelleted cells were collected for RNA extraction, reverse 
transcription and real-time PCR analysis as described above.
Studies in ERV1/ChemR23 gene-deficient mice. Male and female ERV1/ChemR23 knockout mice 
were obtained from Deltagen (San Mateo, CA). Heterozygous mice in the C57BL/6 background were interbred to 
generate homozygous ERV1/ChemR23 knockout mice (n = 12) and their WT controls (n = 12). All experimental 
protocols were approved by the Ethical Committee of Animal Experimentation of the University of Barcelona 
(authorization# 9362) in accordance with the guidelines set by the Direcció General de Polítiques Ambientals i 
Medi Natural of the Generalitat de Catalunya and the regulations of the European Union legislation. Genomic 
DNA from the ear was isolated using the Omni-Pure Tissue Genomic DNA System (Gene Link, Hawthorne, 
NY) following the manufacturer’s protocol and genotyped by PCR. Two different PCR reactions of 20 μL were 
performed for detection of endogenous (E) and targeted (T) alleles. Expected product sizes in base pairs (bp) 
and a schematic diagram of the ERV1/ChemR23 knockout construct are shown in Supplementary Fig. 7A. The 
PCR reactions contained 0.5 µM of primers (forward direction: 5′-TACAGCTTGGTGTGCTTCCTCGGTC-3′ 
(ChemR23 primer or E) and 5′-GGGTGGGATTAGATAAATGCCTGCTCT-3′ (Neo primer or T); reverse direc-
tion: 5′-TGATCTTGCACATGGCCTTCCCGAA-3′ (common E and T)), 0.2 mM dNTPs mix, 1.5 mM MgCl2, 
and 1 U Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA). PCR cycle conditions were 15 min at 95 °C 
followed by 30 cycles of 20 s at 94 °C, 40 s at 62 °C and 1 min at 72 °C, and a final step of 10 min at 72 °C and then 
cooled to 4 °C. PCR bands were separated by electrophoresis in 2.5% LM Sieve agarose gels and visualized by 
GelRedTM Nucleic Acid Gel Stain (Biotium, Hayward, CA) using a 100-bp DNA ladder marker (Invitrogen). 
Gel images of the resulting PCR products of a typical offspring composed by 3 wild-type, 5 heterozygous ERV1/
ChemR23+/− and 1 homozygous ERV1/ChemR23−/− littermates, are shown in Supplementary Fig. 7B. The mice 
were housed in wood-chip bedding cages with 50%-60% humidity under a 12 h light/12 h darkness cycle with 
unlimited access to food and water. At 18 weeks of age, the mice were euthanized via ketamine/xylazine injection 
(i.p., 4:1), and visceral adipose tissue and liver were excised, rinsed in DPBS and snap-frozen in liquid nitrogen 
for RNA analyses. All animal studies were conducted in accordance with the Investigation and Ethics Committee 
criteria of the Hospital Clínic and European Union legislation.
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Isolation of mouse peritoneal macrophages. Isolation of peritoneal macrophages from ChemR23+/−, 
ChemR23−/− and ChemR23+/+ mice was performed as described by Titos et al.9. Briefly, peritoneal macrophages 
were collected by peritoneal lavage with 7 ml ice-cold DPBS−/− three days after the i.p. injection of 2.5 ml of 3% 
thioglycolate. The exudates were centrifuged at 500 g for 5 min at 4 °C and further resuspended in DMEM supple-
mented with penicillin (100 U/ml), streptomycin (100 mg/ml), 2 mM L-glutamine and 5% FBS. The cells (150,000 
cells/well) were allowed to adhere on 6-wells culture plates over 2 h at 37 °C in a humidified 5% CO2 incubator. 
Non-adherent cells were removed by washing twice with DPBS−/− and the remaining adherent cells were used 
for the experiments. Finally, the macrophages were washed twice and then collected in TRIzol reagent and kept at 
−80 °C for RNA extraction and gene expression analysis.
Differentiation and incubation of 3T3-L1 adipocytes. Mouse 3T3-L1 cells were seeded onto six-well 
plates (250,000 cells per well) in DMEM supplemented with 10% (vol/vol) FBS, 100 U/mL penicillin/strepto-
mycin and 4 mM L-glutamine in a humidified atmosphere of 5% CO2 at 37 °C and allowed to grow to con-
fluence for 2 days. Some confluent 3T3-L1 cells were either differentiated with adipocyte induction medium 
or left undifferentiated. The adipocyte induction medium contained insulin (5 μg/mL), isobutylmethylxanthine 
(0.5 mM), dexamethasone (0.25 μM), penicillin/streptomycin (100 U/mL), and L-glutamine (4 mM) in DMEM 
supplemented with 10% FBS. After 2 days, the induced cells were cultured in continuation medium (5 μg/mL 
insulin) for 72 hours and then maintained in DMEM supplemented with 10% FBS until exhibiting an adipocyte 
phenotype at day 8 of differentiation.
Statistical analysis. Study groups were tested for Hardy-Weinberg equilibrium and observed and expected 
allele and genotypic frequencies were compared by χ2 analysis. Sample size calculations were conducted using 
Quanto software version 1.2.4. Allele and genotype frequencies for each SNP were compared between the obese 
and control groups using a 2 × 2 contingency table and calculation of the odds ratio with a 95% confidence inter-
val. The relation of dependence between the minor allele and obesity was studied by Spearman correlation for 
non-parametrical variables. Statistical analysis of anthropometric data and gene expression results was performed 
using the unpaired Student’s t test. The results were expressed as means ± SEM and the level of statistical signifi-
cance was set at P < 0.05.
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